EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

An In Silico–In Vitro Framework for Model‐Informed Precision Dosing in Oncology: Proof‐of‐Principle for Doxorubicin in Patient‐Derived Sarcoma Spheroids

Hannah K Dorn iD, Micaela Freitas, Severin Manser, Marko Weidmann, Ina Oehme, Heike Peterziel iD, Olaf Witt, Jens M Kelm, Lars Kuepfer

Clinical and Translational Science · 2026-11 · 19 (11)

DOI: 10.1111/cts.70774 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, online erschienen am 17.11.2026. Verfasst von Hannah K Dorn und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Systems Medicine With Focus on Organ Interaction, University Hospital RWTH Aachen University, Aachen, Germany. Hauptthemen laut MEDLINE: Doxorubicin, Precision Medicine, Sarcoma, Antibiotics, Antineoplastic. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: H.W. & J. Hector Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug dose and drug exposure time are important factors influencing the tumor‐specific response to pharmacological agents. These parameters are only minimally reflected, if at all, in current functional precision medicine platforms and general prediction algorithms. In this study, we combined individualized pharmacokinetic modeling with functional long‐term in vitro testing in patient‐derived tumor spheroids to allow design of effective dosing regimens for solid tumors. Doxorubicin (DOX), which is used as a standard of care in the treatment of solid tumors such as soft tissue and bone sarcomas, served as a model drug. Based on an individualized physiologically‐based pharmacokinetic DOX model for a 16‐year‐old woman, a series of study conditions were defined using the computationally modeled human area under the curve (AUC) for in vitro testing design. The different conditions spanned a range of treatment conditions from long‐term exposure at low concentrations to short‐term exposure at high concentrations, using patient‐derived soft‐tissue rhabdoid myosarcoma tumor spheroids derived from a 16‐year‐old cancer patient. Consistent with clinical observations, our results indicate that the outcome depended mainly on DOX concentration, while the exposure time was almost insignificant. Moreover, our study showed that the inhibitory DOX effect reaches saturation despite the AUC being linearly dependent on the administered dose such that lower DOX doses with similar antitumoral efficacy, yet lower systemic toxicity, can be achieved. The concept presented here is intended to serve as a foundation for in silico–in vitro research, with the aim of enhancing precision dosing in oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DoxorubicinPrecision MedicineSarcomaAntibiotics, AntineoplasticHumansSpheroids, CellularFemaleAdolescentComputer SimulationProof of Concept StudyModels, BiologicalDose-Response Relationship, DrugTumor Cells, Cultured

Stichwörter der Autor:innen

doxorubicinmodel‐informed precision dosingpatient‐derived tumor spheroidspharmacokinetic–pharmacodynamic (PK/PD) modelingphysiologically‐based pharmacokinetic (PBPK) modelingprecision oncology

Substanzen

DoxorubicinAntibiotics, Antineoplastic

Autor:innen und Institutionen

  • Institute for Systems Medicine With Focus on Organ Interaction, University Hospital RWTH Aachen University, Aachen, Germany.
  • PreComb Therapeutics AG, Hombrechtikon, Switzerland.
  • Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
  • Clinical Cooperation Unit Pediatric Oncology (B310), German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany.
  • National Center for Tumor Diseases Heidelberg, Heidelberg, Germany.
  • Department of Pediatric Oncology, Hematology, Immunology and Pulmonology, Heidelberg University Hospital, Heidelberg, Germany.

ORCID-Profile: Hannah K Dorn, Heike Peterziel

Förderung

  • H.W. & J. Hector Foundation

Zitieren

APA

Dorn, H. K., Freitas, M., Manser, S., Weidmann, M., Oehme, I., Peterziel, H., Witt, O., Kelm, J. M., & Kuepfer, L. (2026). An In Silico–In Vitro Framework for Model‐Informed Precision Dosing in Oncology: Proof‐of‐Principle for Doxorubicin in Patient‐Derived Sarcoma Spheroids. Clinical and Translational Science, 19(11). https://doi.org/10.1111/cts.70774

Vancouver

Dorn HK, Freitas M, Manser S, Weidmann M, Oehme I, Peterziel H, et al. An In Silico–In Vitro Framework for Model‐Informed Precision Dosing in Oncology: Proof‐of‐Principle for Doxorubicin in Patient‐Derived Sarcoma Spheroids. Clinical and Translational Science. 2026;19(11). doi:10.1111/cts.70774

BibTeX
@article{Dorn2026,
  author = {Dorn, Hannah K and Freitas, Micaela and Manser, Severin and Weidmann, Marko and Oehme, Ina and Peterziel, Heike and Witt, Olaf and Kelm, Jens M and Kuepfer, Lars},
  title = {An In Silico–In Vitro Framework for Model‐Informed Precision Dosing in Oncology: Proof‐of‐Principle for Doxorubicin in Patient‐Derived Sarcoma Spheroids},
  journal = {Clinical and Translational Science},
  year = {2026},
  volume = {19},
  number = {11},
  doi = {10.1111/cts.70774}
}
Kostenlos starten →